Drug
Lixumistat acetate clinical trials
Also written IM156.
- studies test it
- 3
- open now
- 1
- in phase 3
- 0
- first study started
- 2017
Keep track of what changes. Save the lixumistat acetate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
3 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 2
M.D. Anderson Cancer Center (1) · ImmunoMet Therapeutics, Inc. (1) · Macarena De La Fuente, MD (1)
Often tested with
Tested in the same studies.
Gemcitabine (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1)
Studies
Open first, then newest update. How each study uses lixumistat acetate is read from its arms, and is right about nine times in ten.
Testing it · 3
- Window of Opportunity Study of Lixumistat in Patients With Newly Diagnosed GlioblastomaRecruitingEarly Phase 1Macarena De La Fuente, MDNCT07884344Written as Lixumistat - Cohort 1
- A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.Active, not recruitingPhase 1M.D. Anderson Cancer CenterNCT05497778Written as IM156
- Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and LymphomaCompletedPhase 1ImmunoMet Therapeutics, Inc.NCT03272256Written as IM156
Codes
What other systems call lixumistat acetate · ClinicalTrials.gg INT015684
- UNII (FDA) 8MS59W493CLIXUMISTAT ACETATEOne source FDA
- NCI Thesaurus C153372Lixumistat AcetateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 8MS59W493C | LIXUMISTAT ACETATE | One source FDA |
| NCI Thesaurus | C153372 | Lixumistat Acetate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.